FH and familial hyperaldosteronism: Regarding the established therapeutic options of pediatric FH, the European Atherosclerosis Society and the American College of Cardiology (American Heart Association) have proposed several guidelines that indicate the importance of lifestyle changes in combination with the initiation of statin therapy, from 8 to 10 years of age for FH heterozygotes and from the time of diagnosis for FH homozygotes [75,77].